2023-02-01 08:06:36 AGRX Agile Therapeutics
02/01/23 02/0108:06 02/01/2308:06 | Agile Therapeutics provides clinical update on Twirla, pipeline evaluationAgile Therapeutics provided an update on the Twirla post-marketing studies and status of its ongoing evaluation of the Company's pipeline. Twirla Post-Marketing Studies: As part of Twirla's approval, the United States Food and Drug Administration required the Company to conduct a long-term prospective, multi-center clinical post-marketing requirement study comparing the risks of venous thromboembolism and arterial thromboembolism in new users of Twirla to new users of combined hormonal contraceptives and Ortho Evra generic patches. In January 2023, the FDA agreed with the Company's proposal to address this PMR using electronic health records and insurance claims from a large database from multiple healthcare systems. The FDA also agreed to extend the study timelines. Under these new milestones, interim safety data reporting to the FDA is due in November 2029, and the final PMR study report is scheduled to be submitted to the FDA in November 2035. Status of Pipeline Evaluation: As previously disclosed, all work on Agile's pipeline has been halted since 2021 as the Company concentrates its efforts the commercialization of Twirla. Commercializing Twirla remains the Company's primary focus into 2023; however, the Company has continued to evaluate the potential eventual advancement of the AG200-15 Extended Regimen and the progestin-only patch. "Our primary focus since the launch of Twirla has been the commercial growth of Twirla. We believe, however, that we have potential value in our pipeline and have been evaluating how to prioritize the eventual development of our product candidates. While we do not currently expect to invest significant funds in our pipeline in 2023 as we continue to focus on maintaining capital efficiency and keeping tight control on our operating expenses, we have been using creative approaches to advance the evaluation of our pipeline and prepare for a time when we can move forward," stated, Al Altomari, Chairman and Chief Executive Officer of Agile Therapeutics.As part of its evaluation of the AG200-15 Extended Regimen, Agile performed an analysis with a simulated pharmacokinetic model that was used to predict the systemic levonorgestrel and ethinyl estradiol exposure of Twirla if used for twelve consecutive weeks. Data from a previously published clinical phase 1, open-label, randomized clinical trial2 was used for the PK model simulation, which included 36 healthy individuals who used a standard Twirla regimen for three consecutive weeks. |
---|
Periodicals
|
Twitter loses another senior executive in charge of content, safety, WSJ says »
17:46 06/03/23 06/0317:46 06/03/2317:46
TWTR
A second senior executive… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Janssen Pharmaceuticals announces updated data from Phase 2 TRiMM-2 study »
17:39 06/03/23 06/0317:39 06/03/2317:39
JNJ
Johnson & Johnson
The Janssen… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Janssen presents analysis of infections, parameters in Monumen-TAL1 study »
17:39 06/03/23 06/0317:39 06/03/2317:39
JNJ
Johnson & Johnson
The Janssen… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Janssen Pharmaceuticals announced results from Phase 1/2 MonumenTAL-1 study »
17:39 06/03/23 06/0317:39 06/03/2317:39
JNJ
Johnson & Johnson
The Janssen… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Replimune Group announces 3 trial-in-progress abstracts at ASCO »
17:26 06/03/23 06/0317:26 06/03/2317:26
REPL
Replimune Group
Additional Abstracts… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Replimune presents data from Phase 1 trial of RP2 with nivolumab at ASCO »
17:26 06/03/23 06/0317:26 06/03/2317:26
REPL
Replimune Group
Bristol-Myers
Replimune Group (REPL)… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Replimune presents RP1 data from IGNYTE trial at ASCO »
17:26 06/03/23 06/0317:26 06/03/2317:26
REPL
Replimune Group
Bristol-Myers
Replimune (REPL)… Story temporarily locked. ShowHide Related Items >><<
|
Conference/Events
| Healthcare Analysts hold… Story temporarily locked. |
Hot Stocks
|
Janssen announces results from Phase 1b RedirecTT-1 study »
17:18 06/03/23 06/0317:18 06/03/2317:18
JNJ
Johnson & Johnson
The Janssen… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Evaxion's trial of EVX-01 met its primary endpoints of safety, tolerability »
17:09 06/03/23 06/0317:09 06/03/2317:09
EVAX
Evaxion Biotech
Evaxion Biotech presented… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Gracell presents long-term follow up data from study evaluating GC012F »
17:07 06/03/23 06/0317:07 06/03/2317:07
GRCL
Gracell
Gracell Biotechnologies… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Sutro Biopharma announces results from Phase 1 dose-expansion study of luvelta »
17:02 06/03/23 06/0317:02 06/03/2317:02
STRO
Sutro Biopharma
Sutro Biopharma announced… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Equitrans Midstream's Mountain Valley Pipeline to proceed »
16:58 06/03/23 06/0316:58 06/03/2316:58
ETRN
Equitrans Midstream
On June 3, 2023, the… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Cogent Biosciences announces data from ongoing Phase 3 PEAK trial »
16:56 06/03/23 06/0316:56 06/03/2316:56
COGT
Cogent Biosciences
Cogent Biosciences… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Gilead, Arcus announce updated results from interim analysis of ARC-7 study »
16:53 06/03/23 06/0316:53 06/03/2316:53
GILD
Gilead
Arcus Biosciences
Gilead Science (GILD) and… Story temporarily locked. ShowHide Related Items >><<
|
Conference/Events
|
Alamo Group participates in a conference call with DA Davidson »
14:27 06/03/23 06/0314:27 06/03/2314:27
ALG
Alamo Group
Analyst Shlisky holds a… Story temporarily locked. ShowHide Related Items >><<
|
Conference/Events
|
Alamo Group management to meet virtually with DA Davidson »
14:04 06/03/23 06/0314:04 06/03/2314:04
ALG
Alamo Group
Analyst Shlisky holds a… Story temporarily locked. ShowHide Related Items >><<
|
Conference/Events
|
Peoples Bancorp management to meet virtually with DA Davidson »
13:59 06/03/23 06/0313:59 06/03/2313:59
PEBO
Peoples Bancorp
Analyst Navas holds a… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
NewAmsterdam's ROSE2 trial on obicetrapib met primary, secondary endpoints »
13:14 06/03/23 06/0313:14 06/03/2313:14
NAMS
NewAmsterdam
NewAmsterdam Pharma… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Precigen announces Phase 1 data of OTS PRGN-2009 AdenoVerse »
13:09 06/03/23 06/0313:09 06/03/2313:09
PGEN
Precigen
Precigen presented… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Elevation Oncology, CSPC announces initial clinical data for SYSA1801 »
13:02 06/03/23 06/0313:02 06/03/2313:02
ELEV
Elevation Oncology
CSPC
Elevation Oncology (ELEV)… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Blueprint Medicines announces data from its VELA trial of BLU-222 »
12:59 06/03/23 06/0312:59 06/03/2312:59
BPMC
Blueprint Medicines
Blueprint Medicines… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Blueprint Medicines announces results from its EGFR Programs »
12:59 06/03/23 06/0312:59 06/03/2312:59
BPMC
Blueprint Medicines
Blueprint Medicines… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Merck announces results from Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA »
12:50 06/03/23 06/0312:50 06/03/2312:50
MRK
Merck
Merck, known as MSD… Story temporarily locked. ShowHide Related Items >><<
|
Hot Stocks
|
Allogene Therapeutics presents updated ALLO-501/501A Phase 1 data »
12:45 06/03/23 06/0312:45 06/03/2312:45
ALLO
Allogene Therapeutics
Allogene Therapeutics… Story temporarily locked. ShowHide Related Items >><<
|